Edition:
United States

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

33.27USD
20 Apr 2018
Change (% chg)

$-0.47 (-1.39%)
Prev Close
$33.74
Open
$33.63
Day's High
$35.00
Day's Low
$33.06
Volume
325,175
Avg. Vol
282,913
52-wk High
$49.15
52-wk Low
$24.68

Chart for

About

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosi... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $1,499.69
Shares Outstanding(Mil.): 45.08
Dividend: --
Yield (%): --

Financials

  RDUS.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -5.80 -- --
ROI: -71.04 -0.74 13.19
ROE: -92.58 -2.80 15.00

BRIEF-Radius Health Initiates Phase 3 Trial Of Abaloparatide Injection For Male Osteoporosis

* RADIUS HEALTH INITIATES PHASE 3 CLINICAL TRIAL OF ABALOPARATIDE INJECTION FOR THE TREATMENT OF MALE OSTEOPOROSIS Source text for Eikon: Further company coverage:

Mar 30 2018

BRIEF-Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC

* RADIUS HEALTH PROVIDES UPDATE ON CHMP OPINION FOR ABALOPARATIDE-SC

Mar 22 2018

BRIEF-Radius Health Reports Q4 Loss Per Share $1.59

* RADIUS HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

Mar 01 2018

BRIEF-Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018

* RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE

Dec 15 2017

BRIEF-Point72 Asset Management Reports 5.1 Percent Passive Stake In Radius Health

* POINT72 ASSET MANAGEMENT, L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN RADIUS HEALTH INC AS OF NOVEMBER 24, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2iXLIQS) Further company coverage:

Nov 27 2017

BRIEF-Radius Health reports Q3 loss per share $1.31

* Radius Health Inc reports third quarter 2017 financial and operating results and provides business update

Nov 02 2017

Earnings vs. Estimates